These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 16323824)

  • 1. Bone morphogenetic proteins and their antagonists: the sclerostin paradigm.
    van Bezooijen RL; Papapoulos SE; Löwik CW
    J Endocrinol Invest; 2005; 28(8 Suppl):15-7. PubMed ID: 16323824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation.
    van Bezooijen RL; ten Dijke P; Papapoulos SE; Löwik CW
    Cytokine Growth Factor Rev; 2005 Jun; 16(3):319-27. PubMed ID: 15869900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of the disease-causing gene in sclerosteosis--discovery of a novel bone anabolic target?
    Balemans W; Van Hul W
    J Musculoskelet Neuronal Interact; 2004 Jun; 4(2):139-42. PubMed ID: 15615113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation.
    van Bezooijen RL; Svensson JP; Eefting D; Visser A; van der Horst G; Karperien M; Quax PH; Vrieling H; Papapoulos SE; ten Dijke P; Löwik CW
    J Bone Miner Res; 2007 Jan; 22(1):19-28. PubMed ID: 17032150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SOST is a target gene for PTH in bone.
    Keller H; Kneissel M
    Bone; 2005 Aug; 37(2):148-58. PubMed ID: 15946907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation.
    Sutherland MK; Geoghegan JC; Yu C; Turcott E; Skonier JE; Winkler DG; Latham JA
    Bone; 2004 Oct; 35(4):828-35. PubMed ID: 15454089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.
    Winkler DG; Sutherland MK; Geoghegan JC; Yu C; Hayes T; Skonier JE; Shpektor D; Jonas M; Kovacevich BR; Staehling-Hampton K; Appleby M; Brunkow ME; Latham JA
    EMBO J; 2003 Dec; 22(23):6267-76. PubMed ID: 14633986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene.
    Balemans W; Cleiren E; Siebers U; Horst J; Van Hul W
    Bone; 2005 Jun; 36(6):943-7. PubMed ID: 15869924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling.
    ten Dijke P; Krause C; de Gorter DJ; Löwik CW; van Bezooijen RL
    J Bone Joint Surg Am; 2008 Feb; 90 Suppl 1():31-5. PubMed ID: 18292354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting sclerostin as potential treatment of osteoporosis.
    Papapoulos SE
    Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i119-22. PubMed ID: 21339215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts.
    Sutherland MK; Geoghegan JC; Yu C; Winkler DG; Latham JA
    Bone; 2004 Aug; 35(2):448-54. PubMed ID: 15268896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist.
    van Bezooijen RL; Roelen BA; Visser A; van der Wee-Pals L; de Wilt E; Karperien M; Hamersma H; Papapoulos SE; ten Dijke P; Löwik CW
    J Exp Med; 2004 Mar; 199(6):805-14. PubMed ID: 15024046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function.
    Piters E; Culha C; Moester M; Van Bezooijen R; Adriaensen D; Mueller T; Weidauer S; Jennes K; de Freitas F; Löwik C; Timmermans JP; Van Hul W; Papapoulos S
    Hum Mutat; 2010 Jul; 31(7):E1526-43. PubMed ID: 20583295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population.
    Staehling-Hampton K; Proll S; Paeper BW; Zhao L; Charmley P; Brown A; Gardner JC; Galas D; Schatzman RC; Beighton P; Papapoulos S; Hamersma H; Brunkow ME
    Am J Med Genet; 2002 Jun; 110(2):144-52. PubMed ID: 12116252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover.
    van Lierop AH; Hamdy NA; Hamersma H; van Bezooijen RL; Power J; Loveridge N; Papapoulos SE
    J Bone Miner Res; 2011 Dec; 26(12):2804-11. PubMed ID: 21786318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sclerostin: current knowledge and future perspectives.
    Moester MJ; Papapoulos SE; Löwik CW; van Bezooijen RL
    Calcif Tissue Int; 2010 Aug; 87(2):99-107. PubMed ID: 20473488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of the SOST bone enhancer by PTH using MEF2 transcription factors.
    Leupin O; Kramer I; Collette NM; Loots GG; Natt F; Kneissel M; Keller H
    J Bone Miner Res; 2007 Dec; 22(12):1957-67. PubMed ID: 17696759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BMP antagonists: their roles in development and involvement in pathophysiology.
    Yanagita M
    Cytokine Growth Factor Rev; 2005 Jun; 16(3):309-17. PubMed ID: 15951218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetics of Sost/SOST in sclerosteosis and van Buchem disease animal models.
    Sebastian A; Loots GG
    Metabolism; 2018 Mar; 80():38-47. PubMed ID: 29080811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sclerostin: a novel target for intervention in the treatment of osteoporosis.
    Lewiecki EM
    Discov Med; 2011 Oct; 12(65):263-73. PubMed ID: 22031665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.